In addition, the quinonemethide triterpenoid compound Pristimerin was shown to suppress VEGF-induced vasculogenesis in a prostate cancer bone metastasis model by blocking the AKT signaling in bone marrow-derived endothelial progenitor cells [138]. This evidence concerns the gene AKT1 and prostate carcinoma.